相关实验视频

Updated: Jul 2, 2025

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

在转移性结直肠癌中使用ctDNA剖析的BRAF变异类,克隆性和共突变的综合景观

Benny Johnson¹, Van Morris¹, Xuemei Wang²

¹Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

|February 24, 2024

概括

转移性结直肠癌 (mCRC) 的非典型BRAF变异是一种独特的亚型. 这些非V600BRAF突变,特别是年轻患者的KRAS/NRAS共变,突显了对新疗法的需求.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
分子生物学分子生物学

背景情况:

转移性结直肠癌 (mCRC) 通常是由BRAF突变驱动的,V600E是最常见的.
非V600 BRAF变体 (非典型的BRAF或aBRAF) 代表了一个独特的分子亚型,具有独特的临床影响.
了解这些非典型的BRAF变体对于开发针对mCRC的向疗法至关重要.

研究的目的:

在mCRC中使用循环瘤DNA (ctDNA) 和临床数据全面描述非典型的BRAF变异.
分析非典型BRAF突变患者的临床结果和分子特征.
在mCRC.中确定非V600 BRAF变异患者的潜在治疗策略.

主要方法:

分析了来自14742名mCRC患者的ctDNA的大型基因组数据库,以确定BRAF变异.
非典型BRAF (II,III类,未分类) 变体的特征及其与RAS突变的同时发生.
在38名具有非典型BRAF变异的mCRC患者队列中对临床结果的回顾性分析.

主要成果:

在14742名mCRC患者中,有1733人患有BRAF变异;非典型的BRAF变异与年轻的男性患者有关.
非典型的BRAF变异,特别是II和III类,与KRAS/NRAS突变的同时发生率增加,特别是在抗EGFR治疗后.
同时发生RAS突变或肝脏干扰预测预后较差;患有aBRAF的50岁以下患者的存活率极低,与KRAS/NRAS共同突变有关.

结论:

非典型的BRAF变体代表了mCRC中独特的分子亚型,具有特定的临床和遗传特征.
在非典型BRAF的年轻患者中,KRAS/NRAS共变的高频率凸显出迫切需要新的治疗策略.
这项研究提供了非典型BRAF变异的全面表征,为未来的mCRC治疗方法提供了信息.

关键词:

这种BRAF突变是BRAF突变.在KRAS突变中发生突变.在NRAS中发生突变.非典型的 BRAF.转移性结直肠癌转移性结直肠癌

更多相关视频

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

相关概念视频

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...